New Bronchodilator – First Of Its Class For Use In Nebulizer
On December 5, 2017, the United States Food and Drug Administration (FDA) announced approval of a new bronchodilator as a long-acting nebulized medication. Lonhala is the brand name of the medication, while the generic name is glycopyrrolate. It is also known as SUN-101/eFlow®. Magnair is the brand name of the eFlow® nebulizer system developed by PARI Pharma GmbH.
According to the FDA, Lonhala Magnair is indicated for “long term, twice each day (morning and evening) maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.”
Why Is It Unique? It is the first long-acting muscarinic antagonist (LAMA) bronchodilator available in a solution to be used in a nebulizer. The other type of bronchodilator is called a beta-agonist. These two classes of bronchodilators work in different ways to open the breathing tubes (airways).
The Magnair nebulizer is a silent and portable delivery device that reduces the amount of time required for someone with COPD to inhale the medication in two to three minutes.
Nebulized medications offer an alternative to metered-dose inhalers, soft mist inhalers, and dry powder inhalers. They allow a person to breathe normally in and out while inhaling the medicine.
Lonhala Magnair is a long-acting bronchodilator delivered by the e-Flow nebulizer
My Comments Lonhala Magnair is the first long-acting muscarinic antagonist bronchodilator available for the nebulized treatment of those with COPD. There are two long- acting nebulized beta-agonist bronchodilators available – Brovana and Perforomist. Both last 12 hours, are used twice daily, and are used with a jet nebulizer.
Soft mist inhaler
I expect that this new bronchodilator will be used in addition to Brovana or Perforomist to provide more effective opening of the breathing tubes (bronchodilation) when a nebulizer is used.
Please view my financial disclosures under the heading ABOUT.
Jet nebulizer system